Record Q1 revenue as U.S. Physical Therapy (NYSE: USPH) reaffirms 2026 outlook. Filing Impact Filing Sentiment Rhea-AI Filing summary. U.S. Physical Therapy, Inc. reported record first quarter 2026 net revenue of $198.3 million, driven by net patient revenue of $164.3 million and other revenue of $34.0 million. Net income attributable to USPH shareholders was $5.0 million, down from $9.9 million a year earlier, with basic and diluted earnings per share at a loss of $0.12 versus earnings of $0.80. Adjusted EBITDA, a key non-GAAP metric, increased to $20.2 million from $19.5 million. Management reaffirmed full year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million, reflecting contributions from two strategic hospital alliances. Upon full integration, these alliances are expected to add at least $6.0 million and $1.3 million of annualized EBITDA to USPH based on its ownership stakes. The board declared a quarterly dividend of $0.46 per share, payable June 12, 2026 to shareholders of record on May 22, 2026. The company ended the quarter with 783 outpatient physical therapy clinics in 44 states and continues to invest in technology, hospital alliances and industrial injury prevention services. Insights. Record revenue and steady EBITDA, but GAAP earnings declined. U.S. Physical Therapy delivered record Q1 2026 net revenue of $198.3M, with net patient revenue up to $164.3M. Segment data show physical therapy net patient revenue rising 7.7% and industrial injury prevention net revenue up 11.8%, indicating broad-based growth. However, GAAP net income attributable to shareholders fell to $5.0M from $9.9M, and earnings per share turned to a loss of $0.12. This shift is tied to items such as changes in fair value of contingent earn-out consideration and revaluation of redeemable non-controlling interests, which also motivate the company's emphasis on non-GAAP metrics. Management reaffirmed 2026 adjusted EBITDA guidance of $102.0M-$106.0M, incorporating phased contributions beginning in May 2026 from two hospital alliances. These are expected to add at least $6.0M and $1.3M in annualized EBITDA to USPH upon full integration, supporting the dividend of $0.46 per share declared for payment on June 12, 2026. 8-K event classification. 3 items: 2.02, 8.01, 9.01 Key figures. Net revenue Q1 2026: $198.3M Net patient revenue Q1 2026: $164.3M Net income attributable to USPH shareholders: $5.0M +5 more Key terms. Adjusted EBITDA, Operating Results, redeemable non-controlling interest, industrial injury prevention, +2 more Earnings snapshot. Net revenue: $198.3M · Guidance included 05/06/2026 - 01:30 PM Faq. How did U.S. Physical Therapy (USPH) perform financially in Q1 2026? U.S. Physical Therapy reported record Q1 2026 net revenue of $198.3 million, up from $183.8 million a year earlier. Net income attributable to USPH shareholders was $5.0 million, compared with $9.9 million in Q1 2025, reflecting higher non-operating and non-controlling interest impacts. What were U.S. Physical Therapy's earnings per share in Q1 2026? For Q1 2026, U.S. Physical Therapy reported basic and diluted earnings per share attributable to shareholders of $(0.12), versus $0.80 in Q1 2025. Shares used in the computation were about 15.2 million in both periods, so the decline mainly reflects lower net income and equity-structure adjustments. What adjusted EBITDA did U.S. Physical Therapy (USPH) generate in Q1 2026? Adjusted EBITDA for Q1 2026 was $20.2 million, slightly above $19.5 million in Q1 2025. This non-GAAP measure adds back items such as interest, taxes, depreciation, amortization, equity-based compensation and fair value adjustments to highlight underlying operating performance. What full year 2026 guidance did U.S. Physical Therapy reaffirm? Management reaffirmed full year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million. This outlook incorporates partial-year contributions from two hospital alliances and the January 1, 2026 Medicare rate increase, with a phased ramp-up beginning in May 2026. How will the new hospital alliances affect U.S. Physical Therapy's EBITDA? Upon full integration, 60 Metro clinics are expected to add at least $12 million in annualized EBITDA to Metro, with about $6 million attributable to USPH. A second partner's ten clinics are expected to add at least $2 million, with around $1.3 million attributable to USPH based on its ownership stakes. What dividend did U.S. Physical Therapy declare in this 8-K filing? The board declared a quarterly cash dividend of $0.46 per common share. It will be payable on June 12, 2026 to shareholders of record as of May 22, 2026, continuing the company's pattern of regular cash returns to shareholders. How many clinics does U.S. Physical Therapy operate after Q1 2026? As of the end of Q1 2026, U.S. Physical Therapy owned or managed 783 outpatient physical therapy clinics in 44 states. This reflects 13 owned clinic additions and 4 owned clinic closures during the quarter, plus changes in managed clinics shown in the roll-forward table. Filing exhibits & attachments. 5 documents Press releases.

U.S. Physical Therapy has closed a $450 million, five-year credit facility comprising a $175 million term loan and a $275 million revolver, maturing 14 April 2031. The facility was upsized from its initial $400 million launch amount due to strong lender support. The new agreement expands and extends the company's previous $325 million credit facility, which was set to expire on 17 June 2027. Bank of America Securities served as joint lead arranger and sole bookrunner, with participation from Regions Capital Markets, US Bank, JP Morgan, Citizens Bank and Bank United. Founded in 1990, U.S. Physical Therapy owns and manages 783 outpatient physical therapy clinics across 44 states and operates an industrial injury prevention business. The company plans to use the facility for acquisitions whilst returning capital to shareholders.

Today's stock news: latest updates on public companies. 328 news published. Markets & banking: quarterly beats and bank sensitivity. Morgan Stanley (MS) reported first-quarter 2026 results, a key read for wealth-management fees and trading revenue that can shift sector sentiment for investors watching fee income and market volatility. PNC (PNC) posted Q1 net income of $1.8 billion and $4.13 diluted EPS, highlighting resilient margins amid changing rates (details). Bank of America (BAC) released Q1 results that remain central to assessing loan growth and consumer credit trends for the broader financial outlook (report). Capital markets & corporate finance: financings that change the math. Revolution Medicines (RVMD) priced an upsized financing of $2.0 billion in stock and convertible notes to extend clinical runway, a near-term headwind for the equity but a funding lifeline for development programs (press release). U.S. Physical Therapy (USPH) secured a $450 million credit facility, boosting optionality for acquisitions and local expansion - items investors watch for margin and same-store growth implications. Graham Corporation (GHM) received a $50 million investment from accounts advised by T. Rowe Price, a material endorsement for backlog execution in industrial engineering (details). AI infrastructure & cloud power: deals and private power. Jane Street (CRWV) signed a $6 billion AI cloud agreement with CoreWeave, underscoring how quant firms are locking long-term compute capacity. For markets, large cloud commitments like this can influence pricing dynamics and providers' capacity planning. Eos Energy Enterprises (EOSE) and TURBINE-X launched a private power infrastructure offering aimed at AI customers, promising hyperscale capacity in months rather than years. This is a direct play on the costly power bottleneck for data centers and may affect demand signals for battery and grid-connection suppliers. Tech, AI & programmatic: efficiency wins, M&A and product expansion. Viant (DSP) agreed to acquire TVision to bolster its AI-driven programmatic TV measurement, a consolidation aimed at improving advertisers' ROI on connected-TV buys. IDCC (IDCC) unveiled an AI-enabled pixel value reduction that cuts energy use and can extend video viewing by up to 22%, a practical efficiency story with implications for streaming platforms and device OEMs. Beeline (BLNE) struck a partnership to integrate embedded mortgage and title solutions into an AI-driven real estate platform - an example of fintech plumbing marrying proptech for potential cross-sell revenue. PayPal (PYPL)'s Venmo continues to broaden beyond peer-to-peer payments into a broader money-movement app for younger users. Investors will watch monetization levers as Venmo expands payments, savings and checkout flows. Biotech & health: trial progress, collaborations and scientific milestones. TG Therapeutics (TGTX) announced completion of enrollment in a Phase 3 trial for subcutaneous BRIUMVI, tightening the timeline for pivotal efficacy data. Allogene Therapeutics (ALLO) highlighted a Nature Communications publication on preclinical data for ALLO-329, its next-gen dual-targeted allogeneic CAR T. Such peer-reviewed exposure can help validate science and support collaboration talks. Tempus (TEM) and Predicta Biosciences announced a collaboration to expand access to an ultrasensitive whole-genome sequencing assay for hematologic malignancies and MRD monitoring, a development that could shift diagnostics and trial enrollment funnels. Quanterix (QTRX) debuted a Content Innovation Engine at AACR 2026, a product story that speaks to platform-led monetization in precision diagnostics. Space, defense & aerospace: commercialization and contracts. RTX (RTX)'s Raytheon completed the first flight test for the RAIVEN(R) sensing system, a milestone for airborne sensing that could influence defense procurement cycles. Sidus Space (SIDU) expanded its agreement with Lonestar Data Holdings to support additional StarVault orbital data storage payloads, building on its earlier StarVault announcement and strengthening the commercial orbital-data-storage narrative for investors watching recurring revenue potential in space-based services. Energy, Mining & resources: commodity moves and resource plays. Mako Mining (MAKO) reported Q1 production of 13,721 oz Au and ~US$69 million in revenue with a debt-free balance sheet and US$96.1 million cash - a strong free-cash narrative for mid-tier gold producers (results). Sprott (SII) launched a Rare Earths Ex-China ETF, reflecting investor demand for supply-chain diversification in critical minerals. Foremost Clean Energy (FMST) reported a high-grade intersection at Hatchet Lake South, an exploration update that can re-rate junior uranium explorers if follow-up drilling expands the zone (details). Industrial & energy services: operational reads. NOV (NOV) provided an operational update for Q1 2026 (update), a report investors use to gauge rig activity, aftermarket demand and services revenue sensitivity to energy prices. Capital markets & structured finance: ratings and securitizations. Pagaya (PGY) achieved an inaugural AAA Fitch rating on a $368 million personal-loan resecuritization. High ratings on consumer credit deals can lower funding costs and support securitization volumes for fintech lenders. Consumer & travel: capacity bets and demand signals. Carnival's Holland America (CCL) announced its largest fleet update in the line's 153-year history, a capital-intensive plan that signals continued confidence in cruise demand and long-term capacity strategy. Giftify (GIFT)'s CardCash reported its highest average buyer order value since 2020, a consumer-intent datapoint that may hint at improving order economics in gift-card channels (release). Autos & mobility: shipments and supply normalization. Stellantis (STLA) estimated Q1 consolidated shipments of 1.4 million units, up 12% y/y, pointing to supply-chain normalization and firmer retail demand across key markets (company note). Selected corporate and product updates investors should note. * Allogene (ALLO)'s Nature Communications paper on ALLO-329 supports the scientific case for its allogeneic CAR-T program (read). * Tempus (TEM) expanded sequencing access with Predicta, a collaboration that can accelerate diagnostic adoption in trials (details). * Quanterix (QTRX) showcased a new content engine at AACR, emphasizing platform monetization in life-science tools (announcement). * Silicom (SILC) won a $3M/yr FPGA Smart NIC contract with a European secure communications leader - meaningful revenue visibility for a niche networking supplier. * Caris Life Sciences (CAI) expanded its right-in-time clinical trial solution to improve access for historically underserved cancer patients, a strategic move in precision oncology trial logistics (release). These items were selected for their likely market impact - earnings and operational reads that affect sector outlooks, financings and ratings that change capital costs, and strategic moves tied to AI, cloud power, diagnostics and space that could reshape long-term growth narratives for investors. Don't miss out on market-moving news. Bookmark this page and check back regularly for the most recent updates on stocks, sectors, and the overall market landscape. Stay informed, stay ahead, and make smarter investment choices with our comprehensive stock news coverage.